Published in Blood on December 15, 1991
Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. J Clin Invest (1993) 2.20
Mice lacking the gene encoding tissue-type plasminogen activator show a selective interference with late-phase long-term potentiation in both Schaffer collateral and mossy fiber pathways. Proc Natl Acad Sci U S A (1996) 1.54
Plasminogen regulates cardiac repair after myocardial infarction through its noncanonical function in stem cell homing to the infarcted heart. J Am Coll Cardiol (2014) 1.45
Impaired arterial neointima formation in mice with disruption of the plasminogen gene. J Clin Invest (1997) 1.44
Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest (1995) 1.42
Enhanced venous thrombus resolution in plasminogen activator inhibitor type-2 deficient mice. J Thromb Haemost (2014) 1.41
Cerebral venous sinus thrombosis. Eur Radiol (2003) 1.34
Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator. J Clin Invest (1996) 1.29
uPA modulates the age-dependent effect of brain injury on cerebral hemodynamics through LRP and ERK MAPK. J Cereb Blood Flow Metab (2008) 1.18
uPA impairs cerebrovasodilation after hypoxia/ischemia through LRP and ERK MAPK. Brain Res (2008) 1.09
Reduced transplant arteriosclerosis in plasminogen-deficient mice. J Clin Invest (1998) 1.08
Receptor-independent role of urokinase-type plasminogen activator in pericellular plasmin and matrix metalloproteinase proteolysis during vascular wound healing in mice. J Cell Biol (1998) 1.03
tPA contributes to impaired NMDA cerebrovasodilation after traumatic brain injury through activation of JNK MAPK. Neurol Res (2011) 1.01
Impaired fibrinolytic system in ApoE gene-deleted mice with hyperlipidemia augments deep vein thrombosis. J Vasc Surg (2011) 0.97
A murine model of myocardial microvascular thrombosis. J Clin Invest (1999) 0.92
Platelet-derived growth factor-C (PDGF-C) activation by serine proteases: implications for breast cancer progression. Biochem J (2012) 0.92
Binding of the COOH-terminal lysine residue of streptokinase to plasmin(ogen) kringles enhances formation of the streptokinase.plasmin(ogen) catalytic complexes. J Biol Chem (2006) 0.90
A Smoothened receptor agonist is neuroprotective and promotes regeneration after ischemic brain injury. Cell Death Dis (2014) 0.89
Cell-type specific DNA-protein interactions at the tissue-type plasminogen activator promoter in human endothelial and HeLa cells in vivo and in vitro. Nucleic Acids Res (1997) 0.87
Anticoagulation and thrombolysis in children. Tex Heart Inst J (1992) 0.86
Plasminogen substrate recognition by the streptokinase-plasminogen catalytic complex is facilitated by Arg253, Lys256, and Lys257 in the streptokinase beta-domain and kringle 5 of the substrate. J Biol Chem (2009) 0.86
Engineering of TEV protease variants by yeast ER sequestration screening (YESS) of combinatorial libraries. Proc Natl Acad Sci U S A (2013) 0.86
Neuroserpin is expressed in the pituitary and adrenal glands and induces the extension of neurite-like processes in AtT-20 cells. Biochem J (2000) 0.86
A high affinity interaction of plasminogen with fibrin is not essential for efficient activation by tissue-type plasminogen activator. J Biol Chem (2011) 0.85
Purification and characterization of a novel fibrinolytic protease from Fusarium sp. CPCC 480097. J Ind Microbiol Biotechnol (2009) 0.83
Laser enhanced high-intensity focused ultrasound thrombolysis: an in vitro study. J Acoust Soc Am (2013) 0.83
Ovulation efficiency is reduced in mice that lack plasminogen activator gene function: functional redundancy among physiological plasminogen activators. Proc Natl Acad Sci U S A (1995) 0.83
tPA contributes to impairment of ATP and Ca sensitive K channel mediated cerebrovasodilation after hypoxia/ischemia through upregulation of ERK MAPK. Brain Res (2010) 0.82
Selective inhibition of GluN2D-containing N-methyl-D-aspartate receptors prevents tissue plasminogen activator-promoted neurotoxicity both in vitro and in vivo. Mol Neurodegener (2011) 0.82
Impacts of tissue-type plasminogen activator (tPA) on neuronal survival. Front Cell Neurosci (2015) 0.80
Proteolytic resistance conferred to fibrinogen by von Willebrand factor. Thromb Haemost (2009) 0.79
The prothrombotic tendency in metabolic syndrome: focus on the potential mechanisms involved in impaired haemostasis and fibrinolytic balance. Scientifica (Cairo) (2012) 0.79
Temperature-sensitive liposome-mediated delivery of thrombolytic agents. Int J Hyperthermia (2015) 0.79
Molecular contributions to neurovascular unit dysfunctions after brain injuries: lessons for target-specific drug development. Future Neurol (2013) 0.79
Decreased fibrinolytic activity in porcine-to-primate cardiac xenotransplantation. Mol Med (1998) 0.79
Plasmin-loaded echogenic liposomes for ultrasound-mediated thrombolysis. Transl Stroke Res (2014) 0.78
Expression of recombinant staphylokinase, a fibrin-specific plasminogen activator of bacterial origin, in potato (Solanum tuberosum L.) plants. World J Microbiol Biotechnol (2012) 0.78
Cryptic peptides of the kringle domains preferentially bind to disease-associated prion protein. J Alzheimers Dis (2009) 0.78
Plasma clot lysis time and its association with cardiovascular risk factors in black Africans. PLoS One (2012) 0.78
Expression of uPA, tPA, and PAI-1 in Calcified Aortic Valves. Biochem Res Int (2014) 0.77
Characterization of plasminogen binding to NB4 promyelocytic cells using monoclonal antibodies against receptor-induced binding sites in cell-bound plasminogen. J Biomed Biotechnol (2012) 0.76
Urokinase plasminogen activator impairs SNP and PGE2 cerebrovasodilation after brain injury through activation of LRP and ERK MAPK. J Neurotrauma (2008) 0.76
The interaction between components of the fibrinolytic system and GPIb/V/IX of platelets thrombus formation in mice. Br J Pharmacol (2000) 0.75
Tranexamic acid-induced ligneous conjunctivitis with renal failure showed reversible hypoplasminogenaemia. BMJ Case Rep (2014) 0.75
Urokinase-type plasminogen activator: a new target for male contraception? Asian J Androl (2015) 0.75
Tissue-type plasminogen activator is a homeostatic regulator of synaptic function in the central nervous system. Neural Regen Res (2017) 0.75
Effect of Fagonia arabica on thrombin induced release of t-PA and complex of PAI-1 tPA in cultured HUVE cells. J Tradit Complement Med (2015) 0.75
Preparation, Optimization and Activity Evaluation of PLGA/Streptokinase Nanoparticles Using Electrospray. Adv Pharm Bull (2017) 0.75
The glycosylation of Bowes melanoma tissue plasminogen activator: lectin mapping, reaction with anti-L2/HNK-1 antibodies and the presence of sulphated/glucuronic acid containing glycans. Biochem J (1996) 0.75
Fibrinolytic Activity of Blood and its Determinants in Healthy Medical Students. J Clin Diagn Res (2015) 0.75
Targeted thrombolysis strategies for neuroprotective effect. Neural Regen Res (2014) 0.75
Carboxypeptidases: new regulators of plasminogen activation in vivo? J Clin Invest (1995) 0.75
Monoclonal antibodies with equal specificity to D-dimer and high-molecular-weight fibrin degradation products. Blood Coagul Fibrinolysis (2016) 0.75
Tissue plasminogen activator for thrombolytic therapy: expectation versus reality. J R Soc Med (1992) 0.75
Expression and activity of the urokinase plasminogen activator system in canine primary brain tumors. Onco Targets Ther (2017) 0.75
Targeting Hypoxia Inducible Factors-1α As a Novel Therapy in Fibrosis. Front Pharmacol (2017) 0.75
Peptides with 6-Aminohexanoic Acid: Synthesis and Evaluation as Plasmin Inhibitors. Int J Pept Res Ther (2016) 0.75
The evolution of recombinant thrombolytics: Current status and future directions. Bioengineered (2016) 0.75
Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem (1982) 3.95
Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler Thromb Vasc Biol (2001) 2.06
Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice. Circulation (1999) 1.97
Coronary thrombolysis: streptokinase or recombinant tissue-type plasminogen activator? Ann Intern Med (1990) 1.88
Reduced atherosclerotic plaque but enhanced aneurysm formation in mice with inactivation of the tissue inhibitor of metalloproteinase-1 (TIMP-1) gene. Circ Res (2002) 1.73
New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost (2008) 1.73
On the specific interaction between the lysine-binding sites in plasmin and complementary sites in alpha2-antiplasmin and in fibrinogen. Biochim Biophys Acta (1979) 1.69
Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity. Arterioscler Thromb Vasc Biol (2000) 1.64
Angiogenesis and development of adipose tissue. Mol Cell Endocrinol (2009) 1.63
Isolation and characterization of a human plasma protein with affinity for the lysine binding sites in plasminogen. Role in the regulation of fibrinolysis and identification as histidine-rich glycoprotein. J Biol Chem (1980) 1.56
Effects of plasminogen activator inhibitor-1 on ischemic brain injury in permanent and thrombotic middle cerebral artery occlusion models in mice. J Thromb Haemost (2005) 1.53
Inactivation of factor XII active fragment in normal plasma. Predominant role of C-1-inhibitor. J Clin Invest (1984) 1.40
Heparin binding properties of human histidine-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma. J Biol Chem (1983) 1.29
Studies on the mechanism of the antifibrinolytic action of tranexamic acid. Biochim Biophys Acta (1981) 1.22
Stromelysin-1 (MMP-3) is critical for intracranial bleeding after t-PA treatment of stroke in mice. J Thromb Haemost (2007) 1.22
Kinetics of the reactions between streptokinase, plasmin and alpha 2-antiplasmin. Eur J Biochem (1979) 1.19
Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators. Thromb Haemost (1989) 1.12
Tissue-type plasminogen activator, a new prognostic marker in breast cancer. Cancer Res (1988) 1.12
A functional role of gelatinase A in the development of nutritionally induced obesity in mice. J Thromb Haemost (2008) 1.10
Strategies for the improvement of thrombolytic agents. Thromb Haemost (1991) 1.10
Structural domains of streptokinase involved in the interaction with plasminogen. Eur J Biochem (1995) 1.09
Interaction of plasminogen activators and inhibitors with plasminogen and fibrin. Semin Thromb Hemost (1982) 1.07
Primary structure of human alpha 2-antiplasmin, a serine protease inhibitor (serpin). J Biol Chem (1987) 1.06
Mouse carotid artery ligation induces platelet-leukocyte-dependent luminal fibrin, required for neointima development. Circ Res (2001) 1.04
Tissue-type plasminogen activator: a historical perspective and personal account. J Thromb Haemost (2004) 1.03
Induction of vascular SMC proliferation by urokinase indicates a novel mechanism of action in vasoproliferative disorders. Arterioscler Thromb Vasc Biol (1997) 1.02
Kinetics of the activation of plasminogen by natural and recombinant tissue-type plasminogen activator. J Biol Chem (1984) 1.02
The tissue-type plasminogen activator story. Arterioscler Thromb Vasc Biol (2009) 0.99
Kinetic properties of tripeptide lysyl chloromethyl ketone and lysyl p-nitroanilide derivatives towards trypsin-like serine proteinases. Biochim Biophys Acta (1980) 0.98
Unveiling an exceptional zymogen: the single-chain form of tPA is a selective activator of NMDA receptor-dependent signaling and neurotoxicity. Cell Death Differ (2012) 0.98
Activation of plasminogen by pro-urokinase. I. Mechanism. J Biol Chem (1986) 0.97
Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits. Blood (1988) 0.96
Staphylokinase, a fibrin-specific plasminogen activator with therapeutic potential? Blood (1994) 0.95
A monoclonal antibody specific for Lys-plasminogen. Application to the study of the activation pathways of plasminogen in vivo. J Biol Chem (1985) 0.95
On the mechanism of the activation of human plasminogen by recombinant staphylokinase. J Biol Chem (1993) 0.95
Purification and characterization of single-chain urokinase-type plasminogen activator from human cell cultures. J Biol Chem (1986) 0.94
Inhibition of trypsin-like serine proteinases by tripeptide arginyl and lysyl chloromethylketones. Thromb Res (1984) 0.94
Plasminogen activation: a mediator of vascular smooth muscle cell apoptosis in atherosclerotic plaques. J Thromb Haemost (2006) 0.94
Physicochemical, immunochemical and functional comparison of human histidine-rich glycoprotein and autorosette inhibition factor. Biochim Biophys Acta (1983) 0.94
The role of plasminogen activator inhibitor type 1 in the inflammatory response to local tissue injury. J Thromb Haemost (2005) 0.93
Haemostasis. Handb Exp Pharmacol (2006) 0.93
Recombinant staphylokinase variants with altered immunoreactivity. I: Construction and characterization. Circulation (1996) 0.93
Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. Circulation (1986) 0.93
Dysfibrinogenemia (fibrinogen Dusard) associated with impaired fibrin-enhanced plasminogen activation. Thromb Haemost (1984) 0.92
Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes. Blood (1998) 0.91
Influence of exogenous and endogenous tissue-type plasminogen activator on the lysability of clots in a plasma milieu in vitro. Thromb Res (1984) 0.91
Plasminogen activator inhibitor-1 contributes to the deleterious effect of obesity on the outcome of thrombotic ischemic stroke in mice. J Thromb Haemost (2007) 0.91
Influence of cyanogen-bromide-digested fibrinogen on the kinetics of plasminogen activation by urokinase. Eur J Biochem (1984) 0.91
Multiple forms of plasminogen activator in human breast tumors. Cancer Res (1985) 0.90
The fibrinolytic system in man. Crit Rev Oncol Hematol (1986) 0.90
Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent. Drugs (1989) 0.90
Amino-acid sequence of human alpha 2-antiplasmin. Eur J Biochem (1987) 0.89
Molecular basis of fibrinolysis, as relevant for thrombolytic therapy. Thromb Haemost (1995) 0.89
Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura. J Thromb Haemost (2010) 0.88
Guiding a docking mode by phage display: selection of correlated mutations at the staphylokinase-plasmin interface. J Mol Biol (1999) 0.88
Purification and characterization of a novel low molecular weight form of single-chain urokinase-type plasminogen activator. J Biol Chem (1986) 0.87
Matrix metalloproteinase deficiencies do not impair cell-associated fibrinolytic activity. Thromb Res (2001) 0.87
Characterization of recombinant human alpha 2-antiplasmin and of mutants obtained by site-directed mutagenesis of the reactive site. Biochemistry (1987) 0.87
Tissue-type plasminogen activator. Ann Biol Clin (Paris) (1987) 0.87
Alpha 2-antiplasmin Enschede: alanine insertion and abolition of plasmin inhibitory activity. Science (1987) 0.86
Thrombolytic therapy. Annu Rev Med (1988) 0.86
Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction. Circulation (1993) 0.86
Comparative immunogenicity and thrombolytic properties toward arterial and venous thrombi of streptokinase and recombinant staphylokinase in baboons. Circulation (1993) 0.86
Deficiency of thrombospondin-1 in mice does not affect adipose tissue development. J Thromb Haemost (2006) 0.85
Chronic relapsing experimental allergic encephalomyelitis (CREAE) in plasminogen activator inhibitor-1 knockout mice: the effect of fibrinolysis during neuroinflammation. Neuropathol Appl Neurobiol (2007) 0.85
Stimulation by heparin of the plasmin-mediated conversion of single-chain to two-chain urokinase-type plasminogen activator. Thromb Res (1986) 0.85
Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro. Thromb Haemost (1986) 0.84
Characterization of a chimeric plasminogen activator consisting of a single-chain Fv fragment derived from a fibrin fragment D-dimer-specific antibody and a truncated single-chain urokinase. J Biol Chem (1991) 0.84
Correlation between progressive adsorption of plasminogen to blood clots and their sensitivity to lysis. Thromb Haemost (1990) 0.84
Turnover of human histidine-rich glycoprotein in healthy subjects and during thrombolytic therapy. Thromb Res (1982) 0.84
Histidine-rich glycoprotein modulates the anticoagulant activity of heparin in human plasma. Thromb Haemost (1984) 0.84
Explanations for coagulation activation after air travel. J Thromb Haemost (2010) 0.84
Fibrin-specific fibrinolysis. Ann N Y Acad Sci (1992) 0.83
Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog. J Am Coll Cardiol (1992) 0.83
Vascular release of plasminogen activator inhibitor-1 impairs fibrinolysis during acute arterial thrombosis in mice. Blood (2000) 0.83
The plasminogen-activation system in ovarian tumors. Int J Cancer (1993) 0.83
Macrophage elastase (MMP-12) in expanding murine adipose tissue. Biochim Biophys Acta (2013) 0.83
Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue. Diabetes (1999) 0.83
A guide to murine fibrinolytic factor structure, function, assays, and genetic alterations. J Thromb Haemost (2007) 0.82
Fibrinolysis and atherosclerosis. Semin Thromb Hemost (1988) 0.82
In vitro prothrombin synthesis from a purified precursor protein. III. Preparation of an acid-soluble substrate for vitamin K-dependent carboxylase by limited proteolysis of bovine descarboxyprothrombin. Biochim Biophys Acta (1981) 0.82
Characterization of a fusion protein consisting of amino acids 1 to 263 of tissue-type plasminogen activator and amino acids 144 to 411 of urokinase-type plasminogen activator. J Biol Chem (1987) 0.82
Proteolytic cleavage of urokinase-type plasminogen activator by stromelysin-1 (MMP-3). Biochemistry (1998) 0.82
New approaches to thrombolytic therapy. Arteriosclerosis (1985) 0.82
Effect of gelatinase inhibition on adipogenesis and adipose tissue development. Clin Exp Pharmacol Physiol (2012) 0.82
Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator. Thromb Haemost (1991) 0.82
Comparative kinetic analysis of the activation of human plasminogen by natural and recombinant single-chain urokinase-type plasminogen activator. Biochim Biophys Acta (1986) 0.82
On the role of the carbohydrate side chains of human plasminogen in its interaction with alpha 2-antiplasmin and fibrin. Eur J Biochem (1981) 0.81
Effect of ageing on the murine venous circulation. Histochem Cell Biol (2012) 0.81
Tissue-type plasminogen activator. Mechanisms of action and thrombolytic properties. Haemostasis (1986) 0.81
Structural and functional basis of plasminogen activation by staphylokinase. Thromb Haemost (1999) 0.81
Mechanism of the enhanced intrinsic activity of single-chain urokinase-type plasminogen activator during ongoing fibrinolysis. J Biol Chem (1993) 0.81
Recommendations for the nomenclature of mutant fibrinolytic genes and their proteins. Report of the SSC Fibrinolysis Subcommittee 1990. Thromb Haemost (1990) 0.81
Modulation of cell-associated plasminogen activation by stromelysin-1 (MMP-3). Thromb Haemost (1999) 0.81
Critical role of glutamic acid 202 in the enzymatic activity of stromelysin-1 (MMP-3). Eur J Biochem (2001) 0.81